Clinical Trial

Phase I Study of LNF1901 in Advanced Malignant Tumors

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 26, 2024 (before its estimated February 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, open, phase I dose-escalation and dose-expansion study to evaluate the safety, tolerability, initial antitumor efficacy, PK and immunogenic characteristics of LNF1901 in patients with advanced malignancies.
Trial Details
NCT Number NCT06226363
Lead Sponsor Shandong New Time Pharmaceutical Co., LTD
Collaborators: Sun Yat-sen University
Conditions Advanced Malignant Tumors
Enrollment 82 participants
Start Date 2024-02-01
Primary Completion 2025-02-01 (estimated)
Study Completion 2027-02-01 (estimated)
Updated on ClinicalTrials.gov 2024-01-26